A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
The main aims of this clinical study are to find out the maximum dose that can be given
safely to patients, the potential side effects of the drug and how they can be managed. The
study will also look at what happens to Anti-CD19 (DI-B4) inside the body.
DI-B4 is a type of drug called an Anti-CD19 monoclonal antibody which is being used to stop
the growth and kill cancerous immune cells by targeting the B-cell marker (CD-19) expressed
on their surface. This drug has not been given to patients before.
DI-B4 will be given weekly by intravenous infusion for four weeks. The study is in two parts.
In Part 1, small groups of patients will be treated at increasing doses to find the highest
safest dose and best dose for part 2 of the study. Approximately 16-20 patients will be
treated in this part. In Part 2, the dose identified in Part 1 will be given to approximately
20 patients.
Patients recruited to the study will receive four weeks (cycles) of treatment. They will
attend an end of therapy visit eight weeks after their last dose of DI-B4, and attend
follow-up visits up to eighteen months after their first dose of DI-B4. Information on the
overall and progression free survival will be collected for a period up to eighteen months
after the final patient is treated on the study.
Patients will have blood and urine samples taken each week during treatment amongst other
clinical tests. CT scans will be performed at the start of the study, at eight weeks post
treatment and six months after the study start. Bone marrow biopsies and FDG-PET scans will
only be taken if needed. Research blood samples will also be taken to look at what happens to
the drug inside the body.
It is important to explain that patients will have advanced cancer so it is unlikely that
patients will benefit directly from taking part but the study may help improve future
treatment of cancer.